Cara Therapeutics (NASDAQ:CARA) Rating Change
Cara Therapeutics (NASDAQ:CARA) was raised by Janney Capital from “Neutral” rating to “Buy” rating in analysts report released on Monday morning.
The company’s rating upgrade is well received by stock speculators, as NASDAQ:CARA is now trading 0.49% higher at $12.43 as of 4:05 PM New York time. Cara Therapeutics shares have [From2] 0% over the last 200 days, while the S&P 500 has added 6.00% for the same time.
Rho Capital Partners Inc had the largest stake with ownership of 3.07M shares as of Q2 2015 for 17.3% of the portfolio. Opaleye Management Inc. is another notably bullish investment professional who is owning 675,000 shares of Cara Therapeutics or 2.95% of their portfolio. Furthermore, Dafna Capital Management Llc have 1.55% of their portfolio invested in the company for 267,046 shares. The California-based fund Wall Street Associates disclosed it had acquired a stake worth about 0.55% of the investment professional’s stock portfolio in Cara Therapeutics. The Massachusetts-based fund Grt Capital Partners L.L.C. is also positive about the stock, possessing 192,300 shares or 0.28% of their portfolio.
Cara Therapeutics (NASDAQ:CARA) Profile
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Cara Therapeutics (NASDAQ:CARA) traded up 0.49% on 12 February, hitting $12.43. A total of 769,099 shares of the company’s stock traded hands. This is up from average of 743,820 shares. Cara Therapeutics has a 52 week low of $5.85 and a 52 week high of $28.5. The company has a market cap of $404.99 million and a P/E ratio of 0.
Get the latest Cara Therapeutics (NASDAQ:CARA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.